Selective cannabinoid receptor 2 modulators: a patent review 2009 – present

Bibliography

• Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996;91:1585-614
   PubMed Web of Science ®Google Scholar
• Matsuda LA, Lolait SJ, Brownstein MJ, Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4
   PubMed Web of Science ®Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5
   PubMed Web of Science ®Google Scholar
• Tanasescu R, Constantinescu CS. Cannabinoids and the immune system: an overview. Immunobiology 2010;215:588-97
   PubMed Web of Science ®Google Scholar
• Lynn AB, Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 1994;268:1612-23
   PubMed Web of Science ®Google Scholar
• Berdyshev EV. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 2000;108:169-90
   PubMed Web of Science ®Google Scholar
• Costa B. On the pharmacological properties of Delta9-tetrahydrocannabinol (THC). Chem Biodivers 2007;4:1664-77
   PubMed Web of Science ®Google Scholar
• Cabral GA, Raborn ES, Griffin L, CB2 receptors in the brain: role in central immune function. Br J Pharmacol 2008;153:240-51
   PubMed Web of Science ®Google Scholar
• Anand U, Otto WR, Sanchez-Herrera D, Cannabinoid receptor CB2 localisation and agonist mediated inhibition of capsaicin responses in human sensory neurons. Pain 2008;138:667-80
   PubMed Web of Science ®Google Scholar
• Turcotte D, Le Dorze JA, Esfahani F, Examining the roles of cannabinoids in pain and other therapeutic indications: a review. Expert Opin Pharmacother 2010;11:17-31
   PubMed Web of Science ®Google Scholar
• Miller AM, Stella N. CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol 2008;153:299-308
   PubMed Web of Science ®Google Scholar
• Whiteside GT, Lee GP, Valenzano KJ. The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr Med Chem 2007;14:917-36
   PubMed Web of Science ®Google Scholar
• Lauckner JE, Jensen JB, Chen HY, GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 2008;105:2699-704
   PubMed Web of Science ®Google Scholar
• Ryberg E, Larsson N, Sjogren S, The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007;152:1092-101
   PubMed Web of Science ®Google Scholar
• Bingham B, Jones PG, Uveges AJ, Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol 2007;151:1061-70
   PubMed Web of Science ®Google Scholar
• Lunn CA. Updating the chemistry and biology of cannabinoid CB2 receptor- specific inverse agonists. Curr Top Med Chem 2010;10:768-78
   PubMed Web of Science ®Google Scholar
• Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 2010;160:467-79
   PubMed Web of Science ®Google Scholar
• Bosier B, Muccioli GG, Hermans E, Lambert DM. Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem Pharm 2010;80:1-12
   PubMed Web of Science ®Google Scholar
• Cabral GA, Marciano-Cabral FJ. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J Leukoc Biol 2005;78:1192-7
   PubMed Web of Science ®Google Scholar
• Carlisle SJ, Marciano-Cabral F, Staab A, Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2002;2:69-82
   PubMed Web of Science ®Google Scholar
• Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 2008;153:319-34
   PubMed Web of Science ®Google Scholar
• Goya P, Jagerovic N. Recent advances in cannabinoid receptor agonists and antagonists. Expert Opin Ther Patents 2000;10:1529-38
   Web of Science ®Google Scholar
• Adam J, Cowley P. Recent advances in the cannabinoids. Expert Opin Ther Patents 2002;12:1475-89
   Web of Science ®Google Scholar
• Hertzog DL. Recent advances in the cannabinoids. Expert Opin Ther Patents 2004;14:1435-52
   Web of Science ®Google Scholar
• Muccioli GG, Lambert DM. Latest advances in cannabinoid receptor antagonists and inverse agonists. Expert Opin Ther Patents 2006;16:1405-23
   Web of Science ®Google Scholar
• Hogenauer EK. Latest advances in the cannabinoids. Expert Opin Ther Patents 2007;17:1457-76
   Web of Science ®Google Scholar
• Thakur GA, Tichkule R, Bajaj S, Makriyannis A. Latest advances in cannabinoid receptor agonists. Expert Opin Ther Patents 2009;19:1647-73
   PubMed Web of Science ®Google Scholar
• Rheinische Friedrich-Wilhelm-Universitat Bonn, Germany. Pharmaceutical Composition containing Cannabinoid-Receptor Antagonists. WO11045068; 2011
   Google Scholar
• INSERM (Institut National de la Santé et de la Recherche Médicale), France. Selective Inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders. WO08122618; 2008
   Google Scholar
• INSERM (Institut National de la Sante et de la Recherche Medicale), France. Selective CB2 receptor agonists for use in prevention or treatment of alcoholic liver disease. WO11009883; 2011
   Google Scholar
• Abbott Laboratories, USA. Combination therapy for reducing side effects using cannabinoid receptor ligands. WO09052342; 2009
   Google Scholar
• McGaraughty S, Chu KL, Dart MJ, A CB2 receptor agonist, A-836339, modulates wide dynamic range neuronal activity in neuropathic rats: contributions of spinal and peripheral CB2 receptors. Neuroscience 2009;158:1652-61
   PubMed Web of Science ®Google Scholar
• University of Pittsburgh, USA. Ligands specific for Cannabinoid Receptor Subtype 2. WO09058377; 2009
   Google Scholar
• Abbott Laboratories, USA. Novel compounds as cannabinoid receptor ligands. WO09114566; 2009
   Google Scholar
• Abbott Laboratories, USA. Imine derivatives as cannabinoid receptor ligands. WO10019547; 2010
   Google Scholar
• Abbott Laboratories, USA. Novel compounds as cannabinoid receptor ligands. WO10033543; 2010
   Google Scholar
• Abbott Laboratories, USA. Novel compounds as cannabinoid receptor ligands. WO10054024; 2010
   Google Scholar
• Abbott Laboratories, USA. Compounds as cannabinoid receptor ligands. WO10111572; 2010
   Google Scholar
• Abbott Laboratories, USA. Compounds as cannabinoid receptor ligands. WO10111573; 2010
   Google Scholar
• Abbott Laboratories, USA. Compounds as cannabinoid receptor ligands. WO10111574; 2010
   Google Scholar
• Abbott Laboratories, USA. Novel compounds as cannabinoid receptor ligands. WO10028338; 2010
   Google Scholar
• Abbott Laboratories, USA. Thiazoles as cannabinoid receptor ligands. WO2010071783; 2010
   Google Scholar
• Abbott Laboratories, USA. Novel compounds as cannabinoid receptor ligands. WO2011159785; 2011
   Google Scholar
• Abbott Laboratories, USA. Prodrug compounds useful as cannabinoid receptor ligands. WO11075522; 2010
   Google Scholar
• Abbott Laboratories, USA. Process for Preparing cannabinoid receptor ligands. WO11075525; 2011
   Google Scholar
• Boehringer Ingelheim Pharma GmbH & Co. KG, Germany. Compounds which modulate the CB2 receptor. WO08039645; 2008. and WO08014199; 2008
   Google Scholar
• Boehringer Ingelheim Pharma GmbH & Co. KG, Germany. Amine and ether compounds which modulate the CB2 receptor. WO08098025; 2008
   Google Scholar
• Boehringer Ingelheim Pharma GmbH & Co. KG, Germany. Sulfone compounds which modulate the CB2 receptor. WO10005782; 2010
   Google Scholar
• Boehringer Ingelheim Pharma GmbH & Co. KG, Germany. Compounds which selective modulate the CB2 receptor. WO10036630; 2010
   Google Scholar
• Boehringer Ingelheim Pharma GmbH & Co. KG, Germany. Compounds which selective modulate the CB2 receptor. WO10036631; 2010
   Google Scholar
• Boehringer Ingelheim Pharma GmbH & Co. KG, Germany. Compounds which selective modulate the CB2 receptor. WO10147792; 2010
   Google Scholar
• Boehringer Ingelheim Pharma GmbH & Co. KG, Germany. Sulfone compounds which modulate the CB2 receptor. WO09140089; 2009
   Google Scholar
• Boehringer Ingelheim Pharma GmbH & Co. KG, Germany. Compounds which selective modulate the CB2 receptor. WO11037795; 2011
   Google Scholar
• Boehringer Ingelheim Pharma GmbH & Co. KG, Germany. Compounds which modulate the CB2 receptor. WO11088015; 2011
   Google Scholar
• Boehringer Ingelheim Pharma GmbH & Co. KG, Germany. Tetrazole compounds which modulate the CB2 receptor. WO11109324; 2011
   Google Scholar
• Boehringer Ingelheim Pharma GmbH & Co. KG, Germany. Azetidine 2-Carboxamide Derivatives which moduulate the CB2 receptor. WO10147791; 2010
   Google Scholar
• Boehringer Ingelheim Pharma GmbH & Co. KG, Germany. Pyrrolidine compounds which modulate the CB2 receptor. WO10077830; 2010
   Google Scholar
• Boehringer Ingelheim Pharma GmbH & Co. KG, Germany. Heterocyclic Compounds which modulate the CB2 receptor. WO10096371; 2010
   Google Scholar
• Glenmark Pharmaceuticals Ltd, India. Novel Cannabinoid receptor ligands, pharmaceutical compositions containing them and process for their preparation. WO08053341; 2008
   Google Scholar
• Glenmark Pharmaceuticals Ltd, India. Novel Cannabinoid receptor ligands, pharmaceutical compositions containing them and process for their preparation. WO06129178; 2006
   Google Scholar
• Glenmark Pharmaceuticals S.A., Switzerland. Novel Cannabinoid receptor ligands, pharmaceutical compositions containing them and process for their preparation. WO09053799; 2009
   Google Scholar
• Arena Pharmaceuticals, Inc., USA. Cannabinoid Receptor Modulators. WO11025541; 2011
   Google Scholar
• Eli Lilly USA. Purine Compounds. WO1080306; 2010
   Google Scholar
• Eli Lilly USA. Purine Compounds used as CB2 Agonists. WO11123482; 2011
   Google Scholar
• Eli Lilly USA. Purine Compounds. WO11123372; 2011
   Google Scholar
• Wyeth LLC, USA. Substituted Oxindole CB2 Agonists for Pain Treatment. WO10077839; 2010
   Google Scholar
• Wyeth LLC, USA. Substituted Oxindole CB2 Agonists. WO10090680; 2010
   Google Scholar
• Raqualia Pharma, Inc., Japan. N-Substituted Saturated Heterocyclic Sulfone Compounds With CB2 receptor Agonistic Activity. WO084767; 2010
   Google Scholar
• Cadila Healthcare Ltd. Substituted benzimidazoles as cannabinoid modulators. WO09116074; 2009
   Google Scholar
• University of Texas Sytem (Austin), USA. Hydrazone Modulators of CB receptors. WO09012227; 2009
   Google Scholar
• University of Texas Sytem (Austin), USA. Heterocyclic Modulators of CB receptors. WO09012221; 2009
   Google Scholar
• Ibrahim MM, Porreca F, Lai J, CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 2005;102:3093-8
   PubMed Web of Science ®Google Scholar
• Ironwood Pharmaceuticals, Inc., USA. Cannabinoid receptor Agonists. WO11100324; 2011
   Google Scholar
• N.V. Organon, Netherlands. 1-(Biphenyl-4-ylmethyl) imidazolidine-2,4-dione Derivatives and their use as CB2 receptor Agonists. WO10063721; 2010
   Google Scholar
• Universite Lille 2 Droit et Sante. 1,4-dihydropyridine derivatives and their uses. WO10133973; 2010
   Google Scholar
• Ipsen Pharma S.A.S. 4-phenyl-1,3-thiazole and 4-phenyl-1,3-oxazole derivatives as cannabinoid receptor ligands. WO09071753; 2009
   Google Scholar
• Giblin GMP, O'Shaughnessy CT, Naylor A, Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl) methyl]-4-(trifluoromethyl)-5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. J Med Chem 2007;50:2597-600
   PubMed Web of Science ®Google Scholar
• Ostenfeld T, Price J, Albanese M, A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction. Clin J Pain 2011;27:668-76
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Co. Fourth Quarter Financial Review, Lilly NME Pipeline January 17, 2012, slide 13
   Google Scholar
• Available from: http://bi.citeline.com/trial_view.asp?trialid=107197&quid=1605088&ob=1&target=5&open=1
   Google Scholar
• Available from: http://media.corporateir.net/media_files/irol/94/94004/presentations/Abbott_Investor_Day_2011.pdf, or http://www.abbottinvestor.com/phoenix.zhtml?c=94004&p=irol-presentations_pf 10/21/11, page 53 and 61
   Google Scholar
• Available from: http://www.kyowa-kirin.co.jp/english/rd/pipeline/pdf/pipeline_e_20111027.pdf
   Google Scholar
• Available from: http://bi.citeline.com/trial_view.asp?trialid=137195&quid=1605097&ob=1&target=5&open=1
   Google Scholar